keyword
MENU ▼
Read by QxMD icon Read
search

Apheresis stem cells

keyword
https://www.readbyqxmd.com/read/28185276/patient-age-and-number-of-apheresis-days-may-predict-development-of-secondary-myelodysplastic-syndrome-and-acute-myelogenous-leukemia-after-high-dose-chemotherapy-and-autologous-stem-cell-transplantation-for-lymphoma
#1
Isabell Ge, Rima M Saliba, Farzaneh Maadani, Uday R Popat, Muzaffar H Qazilbash, Sai Ravi Pingali, Nina Shah, Sairah Ahmed, Qaiser Bashir, Yago Nieto, Richard E Champlin, Chitra Hosing
BACKGROUND: The goal of our study was to find predictors for the development of secondary myelodysplastic syndrome or acute myelogenous leukemia (s-MDS/AML) in patients with relapsed or refractory lymphoma who received high-dose chemotherapy and autologous stem cell transplantation (ASCT). STUDY DESIGN AND METHODS: We conducted a retrospective review of 295 patients with relapsed or refractory lymphoma who had undergone their first stem cell collection and ASCT...
February 10, 2017: Transfusion
https://www.readbyqxmd.com/read/28164682/comparison-of-simultaneous-cd34-and-cd3-quantification-with-a-modified-stem-cell-enumeration-kit-on-two-different-flow-cytometers
#2
Julian Strobel, Barbara Hauck-Dlimi, Volker Weisbach, Reinhold Eckstein, Juergen Zingsem, Erwin Strasser
BACKGROUND: Quantification of CD34+ cells in peripheral blood stem cell apheresis is normally performed by single platform flow cytometric measurements according to the ISHAGE protocol. Peripheral blood stem cell concentrates (PBSC) produced by apheresis normally contain many T cells. Those T cells can be used for production of donor lymphocyte infusion doses, if abundant amounts of CD34+ cells have been collected. Therefore, it is of interest to know both the CD3+ and the CD34+ cell count of allogeneic PBSC...
November 1, 2016: Clinical Laboratory
https://www.readbyqxmd.com/read/28162978/distribution-of-indications-and-procedures-within-the-framework-of-centers-participating-in-the-waa-apheresis-registry
#3
REVIEW
B Stegmayr, M Mörtzell Henriksson, E Newman, V Witt, K Derfler, G Leitner, S Eloot, A Dhondt, D Deeren, G Rock, J Ptak, M Blaha, M Lanska, Z Gasova, Z Bhuiyan-Ludvikova, R Hrdlickova, W Ramlow, H Prophet, G Liumbruno, E Mori, A Griskevicius, J Audzijoniene, H Vrielink, E Rombout-Sestrienkova, A Aandahl, A Sikole, J Tomaz, K Lalic, I Bojanic, V Strineholm, B Brink, G Berlin, J Dykes, F Toss, T Nilsson, F Knutson, B Ramsauer, A Wahlstrom
The WAA apheresis registry was established in 2003 and an increasing number of centers have since then included their experience and data of their procedures. The registry now contains data of more than 74,000 apheresis procedures in more than 10,000 patients. This report shows that the indications for apheresis procedures are changing towards more oncological diagnoses and stem cell collections from patients and donors and less therapeutic apheresis procedures. In centers that continue to register, the total extent of apheresis procedures and patients treated have expanded during the latest years...
January 4, 2017: Transfusion and Apheresis Science
https://www.readbyqxmd.com/read/28139098/predictors-for-successful-pbsc-collection-on-the-fourth-day-of-g-csf-induced-mobilization-in-allogeneic-stem-cell-donors
#4
Anja van Oostrum, Jaap Jan Zwaginga, Sandra Croockewit, Jacqueline Overdevest, Mirjam Fechter, Bart Ruiterkamp, Anneke Brand, Tanja Netelenbos
Peripheral blood stem cells (PBSCs) used for allogeneic transplantation are collected by apheresis after pre-treatment of donors with G-CSF. Using modern apheresis devices stem cells can be collected more efficiently. It was studied whether collection on the 4th instead of the 5th day after initiation of G-CSF treatment might be feasible. Stem cell yields that could have been collected on day 4 were calculated in two cohorts treated with 10 µg/kg G-CSF once daily (n = 106, cohort I) or 5 µg/kg twice daily schedule (n = 85, cohort II)...
January 31, 2017: Journal of Clinical Apheresis
https://www.readbyqxmd.com/read/28115876/management-of-psychiatric-complications-in-unrelated-donor-before-unrelated-peripheral-hematopoietic-stem-cell-collections
#5
Olivier Hequet, Valerie Mialou, Francoise Audat, Eric Wattel, Valerie Chapel, Damiela Revesz, Jean-Piere Jouet, Brigitte Fisseaux, Mohamed Saoud, Mauricette Michallet
Allogeneic hematopoietic stem cell transplantation can efficiently treat patients with severe hematological diseases. A human leukocyte antigen-compatible donor is required for performing transplantation. The occurrence of unexpected acute severe diseases in a donor can compromise the feasibility of allogeneic hematopoietic stem cell transplantation. However, when a severe health problem occurs in a donor while the recipient has already received a conditioning regimen, hematologists have to find the best solutions for the recipient, while the team in charge of the donor has to find the best medical solutions for the donor...
2017: Journal of Blood Medicine
https://www.readbyqxmd.com/read/28109298/neuroregenerative-potential-of-intravenous-g-csf-and-autologous-peripheral-blood-stem-cells-in-children-with-cerebral-palsy-a-randomized-double-blind-cross-over-study
#6
Wee-Jin Rah, Young-Ho Lee, Jin-Hwa Moon, Hyun-Ju Jun, Hye-Ryeong Kang, Hani Koh, Hye Jung Eom, Ji Young Lee, Young Jun Lee, Ji Young Kim, Yun-Young Choi, Kyeongil Park, Mi Jung Kim, Seung-Hyun Kim
OBJECTIVE: We performed a randomized, double-blind, cross-over study to assess the neuroregenerative potential of intravenous granulocyte colony-stimulating factor (G-CSF) followed by infusion of mobilized peripheral blood mononuclear cells (mPBMCs) in children with cerebral palsy (CP). METHODS: Children with non-severe CP were enrolled in this study. G-CSF was administered for 5 days, then mPBMCs were collected by apheresis and cryopreserved. One month later (M1), recipients were randomized to receive either mPBMCs or a placebo infusion, and these treatment groups were switched at 7 months (M7) and observed for another 6 months (M13)...
January 21, 2017: Journal of Translational Medicine
https://www.readbyqxmd.com/read/28089409/the-italian-registry-of-therapeutic-apheresis-2015
#7
REVIEW
Giustina De Silvestro
Data collection on apheresis activities in Italy throughout 2015 including techniques, clinical indications and adverse effects was performed by means of a SidEM model questionnaire (aggregate data). These data provided by 67 Apheresis Units from 17 Italian regions, albeit rough, are sufficiently informative, mainly in comparison with previous surveys on these statistics. PEx has been the most frequent technique for plasma removal/treatment (11787 procedures) followed by LDL-apheresis (927 procedures). ECP/photopheresis has been the most frequent cytapheresis procedure: 6,606 session, mainlyby using the off-line technique...
December 29, 2016: Transfusion and Apheresis Science
https://www.readbyqxmd.com/read/28049490/mobilization-of-hematopoietic-stem-cells-with-the-novel-cxcr4-antagonist-pol6326-balixafortide-in-healthy-volunteers-results-of-a-dose-escalation-trial
#8
Darja Karpova, Susanne Bräuninger, Eliza Wiercinska, Ariane Krämer, Belinda Stock, Jochen Graff, Hans Martin, Achim Wach, Christophe Escot, Garry Douglas, Barbara Romagnoli, Eric Chevalier, Klaus Dembowski, Leon Hooftman, Halvard Bonig
BACKGROUND: Certain disadvantages of the standard hematopoietic stem and progenitor cell (HSPC) mobilizing agent G-CSF fuel the quest for alternatives. We herein report results of a Phase I dose escalation trial comparing mobilization with a peptidic CXCR4 antagonist POL6326 (balixafortide) vs. G-CSF. METHODS: Healthy male volunteer donors with a documented average mobilization response to G-CSF received, following ≥6 weeks wash-out, a 1-2 h infusion of 500-2500 µg/kg of balixafortide...
January 3, 2017: Journal of Translational Medicine
https://www.readbyqxmd.com/read/28013359/comparison-of-engraftment-following-different-stem-cell-mobilization-modalities-in-patients-with-multiple-myeloma-treated-with-a-uniform-induction-regimen-containing-bortezomib-cyclophosphamide-and-dexamethasone
#9
COMPARATIVE STUDY
Noam Benyamini, Irit Avivi, Eldad J Dann, Tsila Zuckerman, Noa Lavi, Tami Katz
Bortezomib-based induction followed by autologous stem cell transplantation is a common treatment for multiple myeloma (MM). Stem cell (SC) mobilization with granulocyte-colony stimulating factor (G-CSF) alone has become an alternative to G-CSF combined with chemotherapeutic agents. This study aimed to compare the efficacy of the two mobilization modalities following induction with a uniform regimen containing bortezomib, cyclophosphamide and dexamethasone (VCD). We retrospectively evaluated results of SC mobilization using either G-CSF alone or combined with high-dose cyclophosphamide (HD-CY) in MM patients after VCD induction...
March 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28009447/modified-cvad-and-modified-cbad-compared-to-high-dose-cyclophosphamide-for-peripheral-blood-stem-cell-mobilization-in-patients-with-multiple-myeloma
#10
Suzanne C Gettys, Alison Gulbis, Kaci Wilhelm, Koji Sasaki, Yvonne Dinh, Gabriela Rondon, Muzaffar H Qazilbash
BACKGROUND: The optimal regimen for peripheral blood stem cell (PBSC) mobilization in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation (auto-HCT) has not been established. Experience at The University of Texas MD Anderson Cancer Center suggests in addition to single-agent cyclophosphamide (Cy), modified cyclophosphamide, vincristine, doxorubicin and dexamethasone (mCVAD), and modified cyclophosphamide, bortezomib, doxorubicin and dexamethasone (mCBAD) may be successful chemomobilization regimens...
December 23, 2016: European Journal of Haematology
https://www.readbyqxmd.com/read/27987208/poor-stem-cell-harvest-may-not-always-be-related-to-poor-mobilization-lessons-gained-from-a-mobilization-study-in-patients-with-%C3%AE-thalassemia-major
#11
Varnavas C Constantinou, Asimina Bouinta, Garyfalia Karponi, Fani Zervou, Penelope-Georgia Papayanni, George Stamatoyannopoulos, Achilles Anagnostopoulos, Evangelia Yannaki
BACKGROUND: Hematopoietic stem cell mobilization and leukapheresis in adult patients with β-thalassemia have recently been optimized in the context of clinical trials for obtaining hematopoietic stem cells for thalassemia gene therapy. In some patients, however, the yield of cluster of differentiation 34-positive (CD34+) cells was poor despite successful mobilization, and a modification of apheresis settings was mandatory for harvest rescue. STUDY DESIGN AND METHODS: Data were analyzed from 20 adult patients with β-thalassemia who were enrolled in a clinical trial of optimizing mobilization strategies for stem cell gene therapy...
December 17, 2016: Transfusion
https://www.readbyqxmd.com/read/27927773/hematopoietic-stem-cell-apheresis-procedure-in-a-context-of-related-allogeneic-transplant-for-acute-myeloid-leukemia-unexpected-outcome-medical-emergency-and-ethical-issue
#12
Marc Bourgeois, Anne Sonet, Francoise Botson, Carlos Graux, Annick Fabry, Marc André, Véronique Deneys
No abstract text is available yet for this article.
December 7, 2016: Haematologica
https://www.readbyqxmd.com/read/27859332/patients-outcome-after-rescue-plerixafor-administration-for-autologous-stem-cell-mobilization-a-single-center-retrospective-analysis
#13
Silvia Spoerl, Robert Peter, Dagmar Wäscher, Katharina Götze, Mareike Verbeek, Christian Peschel, Angela M Krackhardt
BACKGROUND: Plerixafor is predominantly used for patients mobilizing inadequate stem cell numbers for autologous transplantation after stimulation with granulocyte-colony-stimulating factor (G-CSF). STUDY DESIGN AND METHODS: We here report on 300 patients undergoing stem cell mobilization with G-CSF, among them 36 poor mobilizers (CD34+ cell counts < 50 × 10(6) /L blood) receiving G-CSF alone and 49 receiving G-CSF in combination with plerixafor for rescue intervention...
January 2017: Transfusion
https://www.readbyqxmd.com/read/27846612/effect-of-high-dose-plerixafor-on-cd34-cells-mobilization-in-healthy-stem-cell-donors-results-of-a-randomized-crossover-trial
#14
Jeremy Pantin, Enkhtsetseg Purev, Xin Tian, Lisa Cook, Theresa Donohue-Jerussi, Elena Cho, Robert Reger, Matthew Hsieh, Hanh Khuu, Gary Calandra, Nancy L Geller, Richard W Childs
Hematopoietic stem cells can be mobilized from healthy donors using single-agent plerixafor without G-CSF, and following allogeneic transplantation, can result in sustained donor derived hematopoiesis. However, when a single dose of plerixafor is administered at a conventional 240 mg/kg dose, approximately one third of donors will fail to mobilize the minimally acceptable dose of CD34+ cells needed for allogeneic transplantation. We conducted an open-label, randomized trial to assess the safety and activity of high-dose (480 mg/kg) plerixafor in CD34+ cell mobilization in healthy donors...
October 20, 2016: Haematologica
https://www.readbyqxmd.com/read/27792717/-comparison-of-the-effectiveness-of-hematopoietic-cell-mobilization-with-chemotherapy-and-filgrastim-versus-filgrastim-alone-for-autologous-transplant-in-patients-with-lymphoma
#15
César Homero Gutiérrez-Aguirre, Fernando De la Garza-Salazar, Olga Cantú-Rodríguez, Óscar González-Llano, José C Jaime-Pérez, Consuelo Mancias-Guerra, Ricardo García-Sepúlveda, Rosario Salazar-Riojas, David Gómez-Almaguer
INTRODUCTION: Autologous hematopoietic stem cell transplantation is the treatment of choice for high-risk Hodgkin's lymphoma and non-Hodgkin's lymphoma. OBJECTIVE: Compare the capacity to mobilize CD34+ cells for autologous hematopoietic stem cell transplantation using schemes with chemotherapy and without chemotherapy plus filgrastim in patients diagnosed with Hodgkin's lymphoma or non-Hodgkin's lymphoma. MATERIAL AND METHODS: The clinical records of patients with Hodgkin's lymphoma or non-Hodgkin's lymphoma who received an autologous hematopoietic stem cell transplant were analyzed retrospectively...
October 2016: Gaceta Médica de México
https://www.readbyqxmd.com/read/27765663/comprehensive-technical-and-patient-care-optimization-in-the-management-of-pediatric-apheresis-for-peripheral-blood-stem-cell-harvesting
#16
Yoshihiro Ohara, Hitoshi Ohto, Tetsunori Tasaki, Hideki Sano, Kazuhiro Mochizuki, Mitsuko Akaihata, Shogo Kobayashi, Tomoko Waragai, Masaki Ito, Mitsuaki Hosoya, Kenneth E Nollet, Kazuhiko Ikeda, Chitose Ogawa, Takahiro Kanno, Yayoi Shikama, Atsushi Kikuta
BACKGROUND: Pediatric apheresis for peripheral blood stem cell transplantation should be carried out with due concern for low corporeal blood volume and vulnerability to hypocalcemia-related complications, hypovolemic shock, and hypervolemic cardiac overload. STUDY DESIGN AND METHODS: We retrospectively investigated a total of 267 apheresis procedures from 1990 to 2013 on 93 children between 0 and 10 years old, including 89 patients and 4 healthy donors, with body weights of 6...
December 2016: Transfusion and Apheresis Science
https://www.readbyqxmd.com/read/27746781/comparative-analysis-of-clinical-scale-ifn-%C3%AE-positive-t-cell-enrichment-using-partially-and-fully-integrated-platforms
#17
Christoph Priesner, Ruth Esser, Sabine Tischer, Michael Marburger, Krasimira Aleksandrova, Britta Maecker-Kolhoff, Hans-Gert Heuft, Lilia Goudeva, Rainer Blasczyk, Lubomir Arseniev, Ulrike Köhl, Britta Eiz-Vesper, Stephan Klöß
BACKGROUND AND AIMS: The infusion of enriched CMV-specific donor T-cells appears to be a suitable alternative for the treatment of drug-resistant CMV reactivation or de novo infection after both solid organ and hematopoietic stem cell transplantation. Antiviral lymphocytes can be selected from apheresis products using the CliniMACS Cytokine-Capture-System(®) either with the well-established CliniMACS(®) Plus (Plus) device or with its more versatile successor CliniMACS Prodigy(®) (Prodigy)...
2016: Frontiers in Immunology
https://www.readbyqxmd.com/read/27726235/performance-assessment-and-benchmarking-of-autologous-peripheral-blood-stem-cell-collection-with-two-different-apheresis-devices
#18
P Wuchter, M Hundemer, A Schmitt, M Witzens-Harig, P Pavel, J Hillengass, H Goldschmidt, A D Ho, K Lisenko
BACKGROUND: Collection of peripheral blood stem cells (PBSCs) for autologous transplantation is a well-established process. As a new generation of leukapheresis (LP) machines has been launched, measures of benchmarking and quality control need to be defined in order to ensure consistent collection performance. OBJECTIVES: The goal of this project was to establish and evaluate a benchmarking system for autologous PBSC collection. METHODS: This retrospective study evaluated PBSC collection data of 198 patients with symptomatic multiple myeloma in first-line therapy who underwent LP in 2013 and 2014 at our institution...
October 11, 2016: Transfusion Medicine
https://www.readbyqxmd.com/read/27696435/comparison-of-two-apheresis-systems-for-autologous-stem-cell-collections-in-pediatric-oncology-patients
#19
Ehud Even-Or, Alexandra Eden-Walker, Maria Di Mola, Elizabeth McDougall, Tal Schechter, Muhammad Ali, Gordana Svajger, Adam Gassas, Christoph Licht, Joerg Krueger
BACKGROUND: Peripheral stem cell collections can be challenging in the pediatric population and respective experience is limited. Since February 2015 our institution is utilizing the new Spectra Optia (Optia) apheresis device, which has replaced the former COBE Spectra (COBE) device. As a quality initiative we collected and compared collection efficiency (CE2) and other collection variables between the two devices. STUDY DESIGN AND METHODS: In this retrospective study we collected and compared clinical, laboratory, and technical collection data from stem cell collection procedures done with the Optia and COBE devices...
January 2017: Transfusion
https://www.readbyqxmd.com/read/27688610/newly-established-stem-cell-transplant-program-100-days-follow-up-of-patients-and-its-comparison-with-published-indian-literature
#20
Aseem Kumar Tiwari, Dinesh Arora, Ravi C Dara, Pranav Dorwal, Nitin Sood, Ruchira Misra, Sunil Kumar Gupta, Vimarsh Raina, Ashok Kumar Vaid
BACKGROUND: Hematopoietic progenitor stem cell transplantation (HPSCT) is used as a standard treatment option to improve outcome in hematological and nonhematological disorders. It is important for new HPSCT program to look at its patient outcome data and compare it with the published data to evaluate the efficacy of program. AIMS: The aim was to compile and collate the patient outcome data of HPSCT and compare with published reports. MATERIALS AND METHODS: Patient demographics, indications, stem cell harvest by apheresis, dose collected, infusion, engraftment, and follow-up data were collected from hospital information system from 2010 to 2013 in a tertiary care hospital...
July 2016: Indian Journal of Medical and Paediatric Oncology
keyword
keyword
41980
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"